Focus on sharing individual patient data distracts from other ways of improving trial transparency

BMJ (Online)

Volumn 357, Issue , 2017, Pages

  Hoffmann, Tammy ^a   Glasziou, Paul ^a   Beller, Elaine ^a   Goldacre, Ben ^b   Chalmers, Iain ^c  

^a BOND UNIVERSITY   (Australia)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c James Lind Initiative   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BEHAVIOR THERAPY; BIOLOGICAL THERAPY; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DATA PROCESSING; HEALTH CARE COST; HEALTH PRACTITIONER; HUMAN; INFORMATION PROCESSING; MEDICAL DOCUMENTATION; MEDICAL LITERATURE; PATIENT CODING; PHYSIOTHERAPY; PRIORITY JOURNAL; PSYCHIATRIC TREATMENT; PUBLIC HEALTH SERVICE; PUBLICATION; RANDOMIZED CONTROLLED TRIAL (TOPIC); SAFETY PROCEDURE; UNITED STATES; ACCESS TO INFORMATION; CLINICAL TRIAL (TOPIC); INFORMATION DISSEMINATION; PROCEDURES; STATISTICS AND NUMERICAL DATA;

ACCESS TO INFORMATION; CLINICAL TRIALS AS TOPIC; HUMANS; INFORMATION DISSEMINATION; PERIODICALS AS TOPIC;

EID: 85021210129     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.j2782     Document Type: Article

References (34)

1. Taichman DB, Sahni P, Pinborg A, et al. Data sharing statements for clinical trials. BMJ 2017;357:j2372. doi:10.1136/bmj.j2372pmid:28584025.
2. Taichman DB, Backus J, Baethge C, et al. Sharing clinical trial data: a proposal from the International Committee of Medical Journal Editors. JAMA 2016;315:467-8. doi:10.1001/jama.2015.18164pmid:26792562.
3. Vallance P, Chalmers I. Secure use of individual patient data from clinical trials. Lancet 2013;382:1073-4. doi:10.1016/S0140-6736(13)62001-2pmid:24075034.
4. Longo DL, Drazen JM. Data sharing. N Engl J Med 2016;374:276-7. doi:10.1056/NEJMe1516564pmid:26789876.
5. Bauchner H, Golub RM, Fontanarosa PB. Data sharing: an ethical and scientific imperative. JAMA 2016;315:1237-9. doi:10.1001/jama.2016.2420pmid:27002444.
6. Strom BL, Buyse ME, Hughes J, Knoppers BM. Data sharing - is the juice worth the squeeze? N Engl J Med 2016;375:1608-9. doi:10.1056/NEJMp1610336pmid:27783903.
7. Horton R. Offline: data sharing - why editors may have got it wrong. Lancet 2016;388:1143. doi:10.1016/S0140-6736(16)31638-5pmid:27650083.
8. Rockhold F, Nisen P, Freeman A. Data sharing at a crossroads. N Engl J Med 2016;375:1115-7. doi:10.1056/NEJMp1608086pmid:27653563.
9. Rosenbaum L. Bridging the data-sharing divide - seeing the devil in the details, not the other camp. N Engl J Med 2017 Apr 26. [Epub ahead of print.] doi:10.1056/NEJMp1704482.
10. Chalmers I, Glasziou P. Avoidable waste in the production and reporting of research evidence. Lancet 2009;374:86-9. doi:10.1016/S0140-6736(09)60329-9pmid:19525005.
11. Zarin DA, Tse T. Sharing individual participant data (IPD) within the context of the trial reporting system (TRS). PLoS Med 2016;13:e1001946. doi:10.1371/journal.pmed. 1001946pmid:26784335.
12. Macleod MR, Michie S, Roberts I, et al. Biomedical research: increasing value, reducing waste. Lancet 2014;383:101-4. doi:10.1016/S0140-6736(13)62329-6pmid:24411643.
13. Dal-Ré R, Ross JS, Marušić A. Compliance with prospective trial registration guidance remained low in high-impact journals and has implications for primary end point reporting. J Clin Epidemiol 2016;75:100-7. doi:10.1016/j.jclinepi.2016.01.017pmid:26820559.
14. Hooft L, Korevaar DA, Molenaar N, Bossuyt PM, Scholten RJ. Endorsement of ICMJE's clinical trial registration policy: a survey among journal editors. Neth J Med 2014;72:349-55.pmid:25178768.
15. Dechartres A, Ravaud P, Atal I, Riveros C, Boutron I. Association between trial registration and treatment effect estimates: a meta-epidemiological study. BMC Med 2016;14:100. doi:10.1186/s12916-016-0639-xpmid:27377062.
16. What does all trials registered and reported mean? http://www.alltrials.net/find-out-more/all-trials/
17. World Health Organization. WHO data set. http://www.who.int/ictrp/network/trds/en/(accessed 10 Feb 2017).
18. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015;372:1031-9. doi:10.1056/NEJMsa1409364pmid:25760355.
19. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov: the final rule. N Engl J Med 2016;375:1998-2004. doi:10.1056/NEJMsr1611785pmid:27635471.
20. Tang E, Ravaud P, Riveros C, Perrodeau E, Dechartres A. Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles. BMC Med 2015;13:189. doi:10.1186/s12916-015-0430-4pmid:26269118.
21. Riveros C, Dechartres A, Perrodeau E, Haneef R, Boutron I, Ravaud P. Timing and completeness of trial results posted at ClinicalTrials.gov and published in journals. PLoS Med 2013;10:e1001566, discussion e1001566. doi:10.1371/journal.pmed.1001566pmid: 24311990.
22. Pfizer. Disclosure of clinical trial information. 2009. https://www.pfizer.com/files/research/research-clinical-trials/Disclosure-ClinicalTrialsInformation-030209.pdf
23. Batelle Technology Partnership Practice. Biopharmaceutical industry-sponsored clinical trials: impact on state economies. 2015. http://phrma-docs.phrma.org/sites/default/files/pdf/biopharmaceutical-industry-sponsored-clinical-trials-impact-on-state-economies.pdf
24. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. doi:10.1136/bmj.e7586pmid: 23303884.
25. Department of Health and Human Services. Clinical trials registration and results information submission. 2016 https://www.federalregister.gov/documents/2016/09/21/2016-22129/clinical-trials-registration-and-results-information-submission
26. Hoffmann TC, Erueti C, Glasziou PP. Poor description of non-pharmacological interventions: analysis of consecutive sample of randomised trials. BMJ 2013;347:f3755. doi:10.1136/bmj.f3755pmid:24021722.
27. Duff JM, Leather H, Walden EO, LaPlant KD, George TJ Jr. Adequacy of published oncology randomized controlled trials to provide therapeutic details needed for clinical application. J Natl Cancer Inst 2010;102:702-5. doi:10.1093/jnci/djq117pmid:20410466.
28. Mendel J, Goldacre B, Ernst E, Whittle S. Problems with ethical approval and how to fix them: lessons from three trials in rheumatoid arthritis. BMJ 2016;354:i4626. doi:10.1136/bmj.i4626pmid:27613703.
29. Hoffmann TC, Glasziou PP, Boutron I, et al. Better reporting of interventions: template for intervention description and replication (TIDieR) checklist and guide. BMJ 2014;348:g1687. doi:10.1136/bmj.g1687pmid:24609605.
30. Goldacre B, Gray J. OpenTrials: towards a collaborative open database of all available information on all clinical trials. Trials 2016;17:164. doi:10.1186/s13063-016-1290-8pmid: 27056367.
31. Doshi P, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 2013;3:e002496. doi:10. 1136/bmjopen-2012-002496pmid:23447465.
32. Weber WEJ, Merino JG, Loder E. Trial registration 10 years on. BMJ 2015;351:h3572. doi:10.1136/bmj.h3572pmid:26149708.
33. Dal-Ré R, Bracken MB, Ioannidis JP. Call to improve transparency of trials of non-regulated interventions. BMJ 2015;350:h1323. doi:10.1136/bmj.h1323pmid:25820265.
34. Vines TH, Albert AYK, Andrew RL, et al. The availability of research data declines rapidly with article age. Curr Biol 2014;24:94-7. doi:10.1016/j.cub.2013.11.014pmid:24361065.